PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24156425-0	2013	[COX-2 inhibitor celecoxib can suppress the proliferation of FLT3-ITD positive acute myeloid leukemia cells with prominent down regulation of MEK/MCL-1 expression in vitro].	Celecoxib	17-26	mitogen-activated protein kinase kinase 7	Homo sapiens	142-145	
24156425-2	2013	The proliferation inhibition effect of Celecoxib with different doses on the FLT3-ITD positive cells MV4-11 and the FLT3-ITD negative K562 cells was detected by CCK-8 method, the cell apoptosis was determined by flow cytometry, and the MEK, Mcl-1, pAKT expression was tested by Western blot.	Celecoxib	39-48	mitogen-activated protein kinase kinase 7	Homo sapiens	236-239	
24156425-4	2013	Western blot showed that Celecoxib down-regulated the expression of MEK and Mcl-1 but did not change the expression of pAKT obviously on MV4-11 cells, while the expression of Mcl-1 was reduced a little, but no obvious change were found in the expression of MEK and pAKT on K562 cells.	Celecoxib	25-34	mitogen-activated protein kinase kinase 7	Homo sapiens	68-71	
24156425-4	2013	Western blot showed that Celecoxib down-regulated the expression of MEK and Mcl-1 but did not change the expression of pAKT obviously on MV4-11 cells, while the expression of Mcl-1 was reduced a little, but no obvious change were found in the expression of MEK and pAKT on K562 cells.	Celecoxib	25-34	mitogen-activated protein kinase kinase 7	Homo sapiens	257-260	
24156425-5	2013	It is concluded that the Celecoxib can inhibit the proliferation of FLT3-ITD positive AML cells distinctly, and the potential mechanism may be related to the inhibition of the MEK/Mcl-1 signaling pathway.	Celecoxib	25-34	mitogen-activated protein kinase kinase 7	Homo sapiens	176-179